Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Smoking Cessation in Young Adults in Northern Finland
NCT01531049Phase 3
Key facts
- Status
- Completed
- Start
- May 2012
- Primary completion
- Dec 2015
- Countries
- 1
- Modality
- Small Molecules
- Conditions
- nicotine dependence
01
Overview
Phase 3, randomised, double-blind trial of varenicline + nicotine patch in nicotine dependence (4 arms). Primary endpoint: The abstinence rate at 3 months. Started May 2012; status: completed.
02
Design
4 arms- Study design
- RandomizedDouble-blind
Varenicline
Varenicline + Placebo Patch
Nicotine cutaneous patch 15mg
Nicotine Patch 15mg
Nicotine cutaneous patch 10mg
Nicotine Patch 10mg
Placebo cutaneous patch
Placebo Patch
03
Who it enrols
Healthy daily smokers (at least 1 cigarette/day for the last month and 100 cigarettes lifetime) motivated to quit. Excludes those with chronic diseases requiring daily medication, allergies to study drugs, or substance abuse.
04
Endpoints
Primary
The abstinence rate
Secondary
The saliva cotinine verified abstinence rate
The abstinence rate
Beyond the preview
Go deeper on NCT01531049.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01531049.